Fosun Pharma launches new A-share and H-share incentive schemes

Shanghai Fosun Pharmaceutical Group has announced the adoption of a 2025 A-share Stock Option Incentive Plan and a 2025 H-share RSU Scheme. The A-share plan will grant up to 5,726,100 A-share stock options, representing 0.2144% of total company shares, with an exercise price of RMB27.93 per share. Concurrently, the H-share RSU Scheme will grant up to 13,370,500 RSUs, equivalent to 0.5007% of total company shares, with a vesting price of RMB1.00 per share.

Both schemes aim to incentivize executive directors, employee directors, senior management, and core personnel. The A-share plan's initial grant covers 4,580,900 options, while the H-share scheme's first grant proposes 10,696,400 RSUs. Performance appraisal at both the group and individual levels will determine the vesting of these incentives, based on metrics like net profit attributable to the parent and revenue from innovative drugs.

The total estimated cost for the H-share RSU Scheme is RMB1,214 million, to be amortized from 2025 to 2028. Both plans have a maximum validity period of 60 months and are subject to shareholder approval and compliance with applicable listing rules and regulations.